

PHARMACIA CORP /DE/  
Form 11-K  
June 29, 2001

1

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

FORM 11-K

ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF  
1934

For the fiscal year ended December 31, 2000

OR

TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE  
ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission file number 1-2516

A. Full title of the plan and the address of the plan, if different from  
that of issuer named below:

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

B. Name of issuer of the securities held pursuant to the plan and the  
address of its principal executive office:

PHARMACIA CORPORATION  
(fka Monsanto Company)  
100 Route 206 North  
Peapack, New Jersey 07977

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the  
trustees (or other persons who administer the employee benefit plan) have duly  
caused this annual report to be signed by the undersigned hereunto duly  
authorized.

The Pharmacia & Upjohn Employee Savings Plan

By: /s/ Peter J. McCauley

-----  
Peter J. McCauley  
Director, Global Pension & Savings Plan  
Secretary, Administrative Committee - U.S. Plans  
Pharmacia Corporation

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

June 29, 2001

3

THE PHARMACIA & UPJOHN  
EMPLOYEE SAVINGS PLAN

FINANCIAL STATEMENTS

December 31, 2000 and 1999

4

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Index to Financial Statements

December 31, 2000 and 1999

	Page
	----
Report of Independent Accountants	1
FINANCIAL STATEMENTS:	
Statements of Net Assets Available for Plan Benefits as of December 31, 2000 and 1999	2
Statement of Changes in Net Assets Available for Plan Benefits for the year ended December 31, 2000	3
Notes to Financial Statements	4
SUPPLEMENTAL SCHEDULES:	
Schedule of Assets Held for Investment Purposes At End of Year December 31, 2000	17
Schedule of Reportable Transactions for the year ended December 31, 2000	26
Note: Supplemental schedules required by the Employee Retirement Income Security Act of 1974 that have not been included herein are not applicable to the Pharmacia & Upjohn Employee Savings Plan.	

5

[PRICEWATERHOUSECOOPERS LETTERHEAD]

REPORT OF INDEPENDENT ACCOUNTANTS

To the Participants and Administrator of  
The Pharmacia & Upjohn Employee Savings Plan

In our opinion, the accompanying statements of net assets available for plan benefits and the related statement of changes in net assets available for plan benefits present fairly, in all material respects, the net assets available for benefits of The Pharmacia & Upjohn Employee Savings Plan (the "Plan") at December 31, 2000 and 1999, and the changes in net assets available for benefits for the year ended December 31, 2000 in conformity with accounting principles generally accepted in the United States of America. These financial statements

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

are the responsibility of the Plan's management; our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

Our audits were conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplemental schedules of Assets Held for Investment Purposes at Year End as of December 31, 2000 and Reportable Transactions for the year ended December 31, 2000 are presented for the purpose of additional analysis and are not a required part of the basic financial statements but are supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. These supplemental schedules are the responsibility of the Plan's management. The supplemental schedules have been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, are fairly stated in all material respects in relation to the basic financial statements taken as a whole.

/s/ PricewaterhouseCoopers LLP

-----  
PricewaterhouseCoopers LLP

June 13, 2001

6

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Statements of Net Assets Available for Plan Benefits

	DECEMBER 31,	
	2000	1999
	-----	-----
ASSETS:		
Investments, at fair value	\$1,683,304,487	\$1,388,704,265
Investments, at contract value	214,166,263	221,781,807
	-----	-----
Total investments	1,897,470,750	1,610,486,072
	-----	-----
Receivables:		
Company contributions, net of forfeitures	33,568,691	29,204,436
Participant contributions	3,296,318	--
Dividends and interest receivable	4,564,239	4,570,253
Investments sold	1,043,145	--
	-----	-----
Total receivables	42,472,393	33,774,689
	-----	-----
Total assets	1,939,943,143	1,644,260,761
	-----	-----
LIABILITIES:		

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Notes payable	234,700,000	260,700,000
Interest payable	45,975,096	44,308,671
Other	622,757	882,410
	-----	-----
Total liabilities	281,297,853	305,891,081
	-----	-----
NET ASSETS AVAILABLE FOR PLAN BENEFITS	\$1,658,645,290	\$1,338,369,680
	=====	=====

See accompanying notes to the financial statements.

2

7

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Statement of Changes in Net Assets Available for Plan Benefits

		FOR THE YEAR ENDED DECEMBER 31, 2000
		-----
Additions:		
Additions to net assets attributed to:		
Investment income:		
Net appreciation in fair value of investments	\$ 291,400,136	
Interest	15,224,314	
Dividends	60,531,707	
Interest on participants' loans	2,555,587	
	-----	
Total investment income	369,711,744	
Contributions:		
Participant	71,158,334	
Rollovers	7,315,938	
Company, net of forfeitures	34,090,320	
	-----	
Total additions	482,276,336	
	-----	
Deductions:		
Deductions from net assets attributed to:		
Benefits paid to participants	138,041,527	
Plan expenses	979,944	
Interest on notes payable	22,979,255	
	-----	
Total deductions	162,000,726	
	-----	
Net increase	320,275,610	
	-----	
Net assets available for plan benefits:		
Beginning of year	1,338,369,680	
	-----	
End of year	\$1,658,645,290	
	=====	

See accompanying notes to the financial statements.

3

8

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Notes to Financial Statements

December 31, 2000 and 1999

1. DESCRIPTION OF PLAN

The following brief description of the Pharmacia & Upjohn Employee Savings Plan (the "Plan") is provided only for general information. Participants should refer to the Plan document for a more complete description of the Plan's provisions.

GENERAL

Pharmacia Corporation (the "Company") is the sponsor of the Plan. The Plan is a defined contribution plan with two component parts: a Section 401(k) plan and an Employee Stock Ownership Plan (the "ESOP"). The Plan covers substantially all domestic employees of the Company not otherwise covered by another defined contribution plan of the Company.

ADMINISTRATION

The Administrative Committee U.S. Plans is responsible for administering Plan operations in accordance with ERISA plan documents. The Global Benefits Investment Committee is responsible for monitoring Plan investments.

CONTRIBUTIONS

Participants can elect to contribute on a before-tax or after-tax basis from 1% to 18%, in 1% increments, of their Total Pay, as defined in the Plan document. The Internal Revenue Code ("IRC") contains certain limits on participant contributions to a qualified plan, such as a \$10,500 limit on a participant's before-tax contributions during the 2000 calendar year. Other limits also apply to highly compensated employees participating in the Plan.

Participants may also elect to make rollover contributions to the Plan from other qualified defined contribution plans.

Since 1990, matching contributions have been made through the ESOP. The Company matching contributions are the basis for allocating shares of the Company's Convertible Perpetual Preferred Stock ("Preferred Stock") to participants' accounts. Dividends paid to the participants' ESOP accounts are also allocated in Preferred Stock.

The Company will match 100% of participant contributions, from 1% to 5% of Total Pay, in the form of Preferred Stock within the ESOP. The Plan will allocate shares of Preferred Stock to participants such that, at the time of allocation, the total value of the shares allocated is equivalent to the Company match. The value of a share of Preferred Stock will be the closing price of one share of Pharmacia common stock multiplied by a 1.7255 conversion factor.

## Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Cash dividends on Preferred Stock shares allocated to participants' accounts prior to January 1, 2000 are exchanged for additional shares of Preferred Stock using the \$40.30 per-share stated value (the purchase price paid by the ESOP at its inception). Cash dividends on Preferred Stock shares allocated to participants' accounts on or after January 1, 2000 are exchanged for additional shares of Preferred Stock using the Pharmacia common stock price multiplied by the 1.7255 conversion factor.

4

9

### THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

#### Notes to Financial Statements

December 31, 2000 and 1999

The Company contributes to the ESOP cash amounts that are necessary to enable the Plan to make its regularly scheduled payments of principal and interest due on the ESOP's outstanding debt and to release Preferred Stock to cover allocations to participant accounts. Employer dividends paid to the ESOP on the Preferred Stock and certain other funds are also used to repay the debt incurred by the Plan to purchase the Preferred Stock from the Company at the inception of the leveraged ESOP (see Note 4).

#### INVESTMENT OPTIONS

Participant contributions received by the Plan are invested at the direction of the participants in accordance with the terms of the Plan document.

Each participant may direct his or her contributions to the following fund options:

- (a) Income Fund,
- (b) American Balanced Fund,
- (c) Indexed Stock Fund,
- (d) Neuberger Berman Guardian Fund,
- (e) American Century Ultra Fund,
- (f) Templeton Foreign Fund, or
- (g) Pharmacia Common Stock Fund, or
- (h) Any combination of the above, provided that a minimum of five percent and a multiple of one percent is directed to each fund selected.

Participants may elect to transfer or allocate their participant contribution balances and earnings thereon to any of the above funds.

Company matching contributions and earnings thereon are only posted to the ESOP Fund. Upon completing ten years of employment service and attaining age 55, participants are allowed to transfer a portion (up to a specified percentage) of their Pharmacia Common Stock Fund balance (i.e., pertaining to Company contributions and earnings thereon) and their ESOP Fund balance into the other investment fund options.

#### PARTICIPANT ACCOUNTS

Each participant's account is credited with the participant's contributions, Company contributions, and plan earnings. Participants' accounts are valued on a daily basis. The benefit to which a participant is

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

entitled is the benefit that can be provided from the participant's vested account balance.

VESTING

Participants are always 100% vested in their contributions to the Plan and earnings thereon.

As of January 1, 2000, all Company contributions and earnings thereon are 100% vested for all active participants on or after to January 1, 2000.

5

10

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Notes to Financial Statements

December 31, 2000 and 1999

Participants who terminated employment prior to January 1, 2000 with less than five years of employment service and less than three years of participation in the Plan are subject to the vesting schedule below:

YEARS OF PARTICIPATION -----	NON-FORFEITABLE PERCENTAGE -----
1 but less than 2	33 1/3%
2 but less than 3	66 2/3%
3 or more	100%

Participants who cease participation in the Plan may be entitled to forfeited amounts if they re-participate in the Plan within five years.

PARTICIPANT LOANS

The Plan has a loan provision which allows participants to borrow from their fund accounts a minimum of \$500 up to a maximum equal to the lesser of 50% of their vested account balance or \$50,000 (reduced by the highest outstanding loan balance within the previous twelve months). Loan terms range from 1-5 years or up to 10 years for the purchase of a primary residence. Loans for the purchase of a home have a \$3,000 minimum loan amount. The loans are secured by the balance in the participant's account and bear a pre-established interest rate. Interest is credited to the account of the participant. Repayments may not necessarily be made to the same fund from which amounts were borrowed. Repayments are credited to the applicable funds based on the participant's investment elections at the time of repayment.

PAYMENT OF BENEFITS

Participants who leave the Company may elect to receive their vested Plan balance. However, their Pharmacia Common Stock Fund and ESOP accounts may be subject to forfeiture based upon years of participation and service (if the participant terminated employment prior to January 1, 2000).

Benefits are paid either in cash or in cash and Pharmacia common stock. Pharmacia common stock is issued only with respect to the participant's

## Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

accounts in the Pharmacia Common Stock Fund and the ESOP Fund. Upon retirement or death, the full value of the participant's accounts is paid in either a lump sum, in installments or by the purchase of an annuity contract. If a participant elects to receive common stock, each share of the Preferred Stock (based on participant records) will be converted into 1.7255 shares of Pharmacia common stock.

Participants may also elect to make in-service withdrawals subject to certain restrictions.

### MERGER OF PLAN SPONSOR

Effective March 31, 2000, Pharmacia & Upjohn, Inc. merged with the Monsanto Company to form Pharmacia Corporation. As a result of the merger, each share of Pharmacia & Upjohn common stock was exchanged for 1.19 shares of Pharmacia Corporation common stock. In addition, each share of Pharmacia & Upjohn Preferred Stock was exchanged for one share of

6

11

convertible perpetual preferred stock of Pharmacia Corporation. Amounts of common shares presented as of December 31, 1999 throughout this document represent Pharmacia & Upjohn shares prior to applying the 1.19 conversion ratio and amounts of preferred shares presented as of December 31, 1999 represent the equivalent number of Pharmacia & Upjohn preferred shares.

## 2. SUMMARY OF ACCOUNTING POLICIES

### METHOD OF ACCOUNTING

The financial statements of the Plan have been prepared on the accrual basis of accounting.

### USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

### INVESTMENT VALUATION AND INCOME RECOGNITION

Shares of mutual funds are valued at quoted market prices which represent the net asset value of shares held by the Plan at year-end. Common/collective trust funds are stated at redemption value as determined by the trustees of such funds based upon the underlying securities stated at fair value. Investments in money market instruments are generally short-term and are valued at cost, which approximates market. Investments in guaranteed investment contracts ("GICs") and synthetic investment contracts ("SICs") are reported at their contract value by the insurance companies and underlying banks, respectively, because these investments have fully benefit-responsive features (see Note 5). Pharmacia Common Stock is valued at quoted market price as of the last business day of the Plan year. The value of outstanding participant loans is determined based on the outstanding principal balance as of the last day of the Plan year.

Pharmacia Preferred Stock is valued using the higher of the per-share stated value of \$40.30 or the quoted market price of Pharmacia common stock multiplied by 1.7255 on the last business day of the Plan year. (Note: Preferred Stock share balances maintained by the Plan's trustee and



## Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

recordkeeper are on a basis equal to one-thousandth of the share balance reflected on the Company's financial statements and the \$40,300 stated value.)

Purchases and sales of securities are reflected on a trade-date basis. Dividend income is recorded on the ex-dividend date. Income from other investments is recorded as earned on an accrual basis.

The Plan presents in the statement of changes in net assets available for plan benefits, the net appreciation (depreciation) in the fair value of its investments which consists of the realized gains and losses and the unrealized appreciation (depreciation) on those investments.

### PAYMENT OF BENEFITS

Benefit payments are recorded when paid.

7

12

## THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

### Notes to Financial Statements

December 31, 2000 and 1999

### PLAN EXPENSES

The Plan pays certain outside service provider expenses (e.g., recordkeeping and trustee fees) incurred in the operation of the Plan. Investment manager fees are paid by the Plan and are netted against investment income. Certain other expenses are paid by the Company.

### FORFEITURES

Forfeited amounts are used to pay expenses of the Plan, interest on ESOP debt incurred by the Plan and to reduce Company contributions. Forfeitures which have not been utilized amounted to \$21,630 and \$599,130 as of December 31, 2000 and 1999, respectively.

### RISKS AND UNCERTAINTIES

The Plan provides for various investment options in any combination of stocks, mutual funds, common/collective trusts, and other investment securities. Investment securities are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in risks in the near term would materially affect participants' account balances and the amounts reported in the statement of net assets available for plan benefits and the statement of changes in net assets available for plan benefits.

### 3. INVESTMENTS

The following presents investments that represent 5 percent or more of the Plan's net assets.

DEC

-----  
2000  
-----

Neuberger Berman Guardian Fund (4,836,623 and 3,978,639 units, respectively)	\$ 71,775,488
Indexed Stock Fund (6,596,621 and 6,424,626 units, respectively)	243,745,143
American Century Ultra Fund (5,292,897 and 4,010,145 units, respectively)	171,331,060
Pharmacia Common Stock (5,052,303 and 4,680,178 shares, respectively)*	308,190,483
Pharmacia Preferred Stock (6,517,533 and 6,692,442 shares, respectively)*	686,006,172

\*Nonparticipant-directed

8

13

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Notes to Financial Statements

December 31, 2000 and 1999

During 2000, the Plan's investments (including gains and losses on investments bought and sold, as well as held during the year) appreciated in value by \$291,400,136 as follows:

	2000
	-----
Mutual funds	\$ (78,044,734)
Common Stock	128,181,196
Preferred Stock	264,879,002
Common/collective trust funds	(23,615,328)
	-----
	\$ 291,400,136
	=====

4. NONPARTICIPANT-DIRECTED INVESTMENTS

PHARMACIA COMMON STOCK FUND

Effective April 1, 1999, the Pharmacia Common Stock Fund was added as an investment option into which participants can direct their contributions and/or transfer existing balances. However, certain Company contribution balances (and earnings thereon) within the Pharmacia Common Stock Fund can only be transferred out of the fund into other investment options after participants satisfy certain age and service requirements. All assets and activity within this fund have been disclosed as nonparticipant-directed for purposes of this report.

Below are the net assets and significant components of the changes in net assets relating to the Pharmacia Common Stock Fund:

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

	2000 -----	1999 -----
Investments:		
Short-term investment funds	\$ 1,747,268	\$ 3,721,116
Pharmacia Common Stock	308,190,483	210,608,010
	-----	-----
Total investments	309,937,751	214,329,126
Receivables:		
Dividends and interest receivable	14,993	15,251
Participant contributions	221,197	--
Receivable from other investment funds	--	107,173
Investments sold	1,036,379	--
	-----	-----
Total receivables	1,272,569	122,424
Liabilities:		
Payable to other investment funds	278,076	--
Other liabilities	1,885	8,816
	-----	-----
Total liabilities	279,961	8,816
Net assets available for plan benefits	\$310,930,359 =====	\$214,442,734 =====

9

14

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Notes to Financial Statements

December 31, 2000 and 1999

	YEAR ENDED DECEMBER 31, 2000 -----
Additions:	
Additions to net assets attributed to:	
Investment income:	
Net appreciation	\$128,181,196
Interest	168,984
Dividends	3,690,575
	-----
Total investment income	132,040,755
Participant contributions (including rollovers)	4,657,347
	-----
Total additions	136,698,102
Deductions:	
Deductions from net assets attributed to:	
Transfers to other investment funds, net	8,475,130

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Benefits paid to participants	31,643,700
Plan expenses	91,647
	-----
Total deductions	40,210,477
	-----
Net increase	96,487,625
Net assets available for plan benefits:	
Beginning of year	214,442,734
	-----
End of year	\$310,930,359
	=====

ESOP AND NOTES PAYABLE

On March 1, 1990, the ESOP borrowed \$275 million from the Bank of New York through the issuance of amortizing notes. These notes, which are guaranteed by the Company, mature in 2004 and pay interest at an annual rate of 9.79%. The proceeds of this debt were paid to the Company to liquidate \$275 million of an original \$300 million loan from the Company to the ESOP. The remaining principal balance on these notes was \$189,700,000 with unpaid interest of \$18,571,630 and \$217,700,000 with unpaid interest of \$21,312,830 as of December 31, 2000 and 1999, respectively.

As of March 1, 1990, the ESOP also issued a new note to the Company in settlement of the remaining balance on the original ESOP loan. This note, in the amount of \$25 million, carries an interest rate of 6.25% per annum. Interest accrues and is payable, along with principal, no later than the maturity date of February 1, 2005. The balance of this note, including unpaid interest, was \$48,225,811 and \$45,388,998 at December 31, 2000 and 1999, respectively.

10

15

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Notes to Financial Statements

December 31, 2000 and 1999

Effective January 31, 1997, the ESOP and State Street Bank entered into an agreement, whereby the ESOP can borrow amounts that in the aggregate cannot exceed \$95,000,000 (collectively the "New Loans"). Any such borrowings bear interest at 7.00% per annum and will be due no later than December 31, 2010. No interest shall be due until the maturity date of any New Loans. The proceeds of each New Loan are to be used to pay principal and interest then due on any existing ESOP loans. In relation to New Loans, the ESOP had drawings of \$20,000,000 with unpaid interest of \$4,177,655 and \$18,000,000 with unpaid interest of \$2,606,843 as of December 31, 2000 and 1999, respectively.

Projected loan payments on the ESOP debt (net of future New Loans) are as follows:

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

YEAR	AMOUNT
2001	\$ 32,800,000
2002	38,871,645
2003	33,898,058
2004	39,456,269
2005 to 2010	89,674,028
Total	\$ 234,700,000

Following are the net assets and significant components of the changes in net assets relating to the ESOP:

11

16

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Notes to Financial Statements

December 31, 2000 and 1999

	ALLOCATED	DECEMBER 31, 2000 UNALLOCATED	TOT
Investments:			
Short-term investment funds	\$ --	\$ 13,368,267	\$ 13,368,267
Pharmacia Preferred Stock, convertible	306,352,473	379,653,699	686,006,172
Total investments	306,352,473	393,021,966	699,374,439
Receivables:			
Dividends and interest receivable	--	4,372,180	4,372,180
Company contributions, net of forfeitures	--	33,568,691	33,568,691
Other receivables	--	5,348	5,348
Total receivables	--	37,946,219	37,946,219
Liabilities:			
Notes payable	--	234,700,000	234,700,000
Interest payable	--	45,975,096	45,975,096
Total liabilities	--	280,675,096	280,675,096
Net assets available for plan benefits	\$306,352,473	\$150,293,089	\$456,645,562

DECEMBER 31,  
1999

ALLOCATED

UNALLOCATED

TO

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Investments:				
Short-term investment funds	\$	--	\$ 13,583,734	\$ 13,5
Pharmacia Preferred Stock, convertible		165,753,679	270,928,168	436,6
		-----	-----	-----
Total investments		165,753,679	284,511,902	450,2
		-----	-----	-----
Receivables:				
Dividends and interest receivable		--	4,455,913	4,4
Company contributions, net of forfeitures		--	29,204,436	29,2
Other receivables		--	23,029	
		-----	-----	-----
Total receivables		--	33,683,378	33,6
		-----	-----	-----
Liabilities:				
Notes payable		--	260,700,000	260,7
Interest payable		--	44,308,671	44,3
		-----	-----	-----
Total liabilities		--	305,008,671	305,0
		-----	-----	-----
Net assets available for plan benefits	\$	165,753,679	\$ 13,186,609	\$178,9
		=====	=====	=====

12

17

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Notes to Financial Statements

December 31, 2000 and 1999

	YEAR ENDED DECEMBER	
	ALLOCATED	UNALLOCATED
	-----	-----
Additions:		
Additions to net assets attributed to:		
Investment income:		
Net appreciation	\$ 115,724,628	\$ 149,154,37
Interest	--	536,50
Dividends	6,807,987	9,760,45
	-----	-----
Total investment income	122,532,615	159,451,33
Company contributions, net of forfeitures	--	34,090,32
Allocation of 382,184 shares of Preferred Stock for Company matching contributions	33,455,917	--
	-----	-----
Total additions	155,988,532	193,541,65
	-----	-----
Deductions:		
Deductions from net assets attributed to:		
Benefits paid to participants	(14,798,168)	--
Interest on notes payable	--	(22,979,25
Transfers to other investment funds	(591,570)	--

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Allocation of 382,184 shares of Preferred Stock for Company matching contributions	--	(33,455,91
	-----	-----
Total deductions	(15,389,738)	(56,435,17
	-----	-----
Net increase	140,598,794	137,106,48
Net assets available for plan benefits:		
Beginning of year	165,753,679	13,186,60
	-----	-----
End of year	\$ 306,352,473	\$ 150,293,08
	=====	=====

5. INVESTMENT CONTRACTS WITH INSURANCE COMPANIES

The Income Fund consists primarily of benefit responsive GICs and SICs. The contract value of the GICs and SICs represents the cost or book-value of the contract plus accrued interest. At December 31, 2000 and 1999, the Plan held GICs with a contract value of \$30,147,174 and \$40,474,517, respectively. The contract value of the SICs represents fair value of the underlying asset plus the book-value of the wrapper contract associated with the underlying asset. At December 31, 2000 and 1999, SIC fair values were \$185,229,622 and \$177,738,536, respectively. Participants may ordinarily direct the withdrawal or transfer of all or a portion of their investment at contract value.

There are no reserves against contract value for credit risk of the contract issuers or otherwise. The average portfolio yield and crediting interest rates were approximately 6% for 2000 and 1999. The crediting interest rate for GICs is based on a formula agreed upon with the issuers and is maintained for the life of the contract. For SICs, the rate is based on a formula which consists of the yield to maturity, duration, and the book and market values. The rate for SICs is periodically reset, usually quarterly, and cannot be reset below 0%.

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Notes to Financial Statements

December 31, 2000 and 1999

6. RECONCILIATION OF FINANCIAL STATEMENTS TO FORM 5500

The following is a reconciliation of net assets available for plan benefits according to the financial statements to Form 5500.

	-----	DECE
	-----	2000
	-----	-----
Net assets available for plan benefits per the financial statements	\$	1,658,645,290

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Amounts allocated to withdrawing participants	(1,075,946)
	-----
Net assets available for plan benefits per Form 5500	\$ 1,657,569,344
	=====

The following is a reconciliation of benefits paid to participants according to the financial statements to Form 5500:

	YEAR ENDED DECEMBER 31, 2000
	-----
Benefits paid to participants per the financial statements	\$ 138,041,527
Add: Amounts allocated to withdrawing participants at December 31, 2000	1,075,946
Less: Amounts allocated to withdrawing participants at December 31, 1999	(1,533,534)
	-----
Benefits paid to participants per Form 5500	\$ 137,583,939
	=====

Amounts allocated to withdrawing participants are recorded on Form 5500 for benefit claims that have been processed and approved for payment prior to December 31 but not yet paid as of that date.

7. RELATED-PARTY TRANSACTIONS

The Plan holds shares of Pharmacia common stock and preferred stock. At December 31, 2000 and 1999, the Plan owned 5,052,303 and 4,680,178 shares of Pharmacia Corporation common stock at a cost of \$87,782,347 and \$75,850,797, respectively. At December 31, 2000 and 1999, the Plan owned 6,517,533 and 6,692,442 shares of Pharmacia Corporation preferred stock at a cost of \$262,656,580 and \$269,705,413, respectively. In addition, Plan funds are invested in a short-term investment fund as well as SICs issued by State Street Bank & Trust Company, a trustee of the Plan. At December 31, 2000 and 1999, the fair value of the State Street Bank & Trust Company short term investment account was \$43,355,639 and \$40,622,685, respectively and the contract value of the SICs was \$15,232,902 and \$22,067,683, respectively. At December

14

19

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Notes to Financial Statements

December 31, 2000 and 1999

31, 1999, Plan funds were also invested in short-term investment funds issued by the Bank of New York, a prior trustee of the Plan, the fair value of which was \$2,433,421.

8. PLAN TERMINATION



Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of Plan termination, participants would become 100 percent vested in their entire plan balance (including match and discretionary contributions and earnings thereon).

9. TAX STATUS OF THE PLAN

The Plan obtained its latest determination letter on April 18, 1996, in which the Internal Revenue Service indicated that the Plan, as then designed, was in compliance with the applicable requirements of the IRC. The Plan has been amended since receiving the determination letter. However, the Company believes that the Plan is currently designed and being operated in compliance with the applicable requirements of the IRC. Therefore, no provision for income taxes has been included in the Plan's financial statements.

15

20

SUPPLEMENTAL SCHEDULES

21

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Assets Held for Investment Purposes at End of Year

December 31, 2000

EIN# 38-1123360

Plan# 002

(a)	(b) IDENTITY OF ISSUE, BORROWER, LESSOR, OR SIMILAR PARTY	(c) DESCRIPTION OF INVESTMENT INCLUDING MATURITY DATE, RATE OF INTEREST, COLLATERAL, PAR, OR MATURITY	(d) COST
	Common Stock:		
*	Pharmacia Corporation	Common stock, \$2.00 par value; 5,052,303 shares	\$ 87,782,3
	Total common stock		\$ 87,782,3
	Preferred stock:		
*	Pharmacia Corporation convertible - unallocated	Preferred stock, \$.01 par value; 3,606,973 shares	\$ 145,361,0
*	Pharmacia Corporation convertible - allocated	Preferred stock, \$.01 par value; 2,910,560 shares	117,295,5
	Total preferred stock		\$ 262,656,5
	Mutual Funds:		
	American Century Ultra	Mutual fund: 5,292,897 units	\$ 173,922,2

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

American Balanced	Mutual fund: 4,068,225 units	59,875,3
Neuberger Berman Guardian	Mutual fund: 4,836,623 units	96,837,7
Templeton Foreign	Mutual fund: 6,364,381 units	62,632,5
Total mutual funds		\$ 393,267,7
-----		
Common/Collective Trust Funds:		
Barclays Global Investors	Common/Collective Trust Fund:	
Equity Index Fund	6,596,621 units	\$ 139,915,4
Total Common/Collective Trust Fund		\$ 139,915,4
-----		
Short-Term Investment Funds:		
* State Street Bank & Trust Co.		
Short-Term Investment Fund	Money market fund	\$ 43,355,6
Total Short-Term Investment Funds		\$ 43,355,6
=====		

-----  
 \* Represents a party-in-interest to the Plan.

17

22

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Assets Held for Investment Purposes at End of Year

December 31, 2000

EIN# 38-1123360  
 Plan# 002

(a)	(b)	(c)	(d)
	IDENTITY OF ISSUE, BORROWER, LESSOR, OR SIMILAR PARTY	DESCRIPTION OF INVESTMENT INCLUDING MATURITY DATE, RATE OF INTEREST, COLLATERAL, PAR, OR MATURITY	COST
	Guaranteed investment contracts - insurance companies:		
	American Int'l Life ICON		
	Contract No. GIC-18305	Interest rate: 5.73%	
		Maturity date: 11/06/2003	\$ 7,891,1
	John Hancock Mutual Life Ins. Co.		
	Contract No. GAC-14500	Interest rate: 5.90%	7,792,5
		Maturity date: 02/10/2004	
	New York Life Insurance Co.		
	Contract No. GA30681	Interest rate: 6.75%	6,329,5
		Maturity Date: 04/02/2001	
	Principal Mutual Life Ins. Co.		
	Contract No. 4238722	Interest rate: 7.03%	5,083,3
		Maturity date: 09/29/2003	
	Travelers Insurance Co.		

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Contract No. GR17755	Interest rate: 7.10%	3,050,5
	Maturity date: 07/31/2003	-----
Total Guaranteed Investment Contracts - Contract Value		\$ 30,147,1
		=====

18

23

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Assets Held for Investment Purposes at End of Year

December 31, 2000

EIN# 38-1123360

Plan# 002

(a)	(b)	(c) DESCRIPTION OF INVESTMENT INCLUDING MATURITY DATE, RATE OF INTEREST, COLLATERAL, PAR, OR MATURITY	(d) COST
Synthetic Investment Contracts**:			
AIG Financial Products			
(3 contracts)			
	Contract No. 143308	Wrapper Contract GT 1996-4 A4	
		Total Contract Value	\$ 298,8
		Interest rate: 6.68%	
		Maturity date: 03/15/2001	
	Contract No. 180162	Wrapper Contract American Express 97-1 (A)	
		Total Contract Value	5,055,3
		Interest rate: 5.95%	
		Maturity date: 09/16/2002	
	Contract No. 212753	Wrapper Contract First USA 1997-6 (A) FUSAM	
		Total Contract Value	7,130,2
		Interest rate: 5.40%	
		Maturity date: 07/17/2002	
Chase Manhattan Bank			
(6 contracts)			
	Contract No. 400176	Wrapper Contract Sears 96-1 (A) SCAMT	
		Total Contract Value	3,121,3
		Interest rate: 6.99%	
		Maturity date: 03/15/2002	

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Contract No. 400180

Wrapper Contract  
FH R 1697 PH

Total Contract Value  
Interest rate: 7.10%  
Maturity date: 02/18/2003

7,436,1

-----  
\*\* A synthetic investment contract is comprised of two components, an underlying asset and a wrapper contract. The underlying asset is valued at representative quoted market prices. The wrapper contract is valued as the difference between the fair value of the underlying asset and the contract value. Contract value represents contributions made under the contract, plus earnings, less Plan withdrawals and administrative expenses. The wrapper contract guarantees the Plan contract value.

19

24

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Assets Held for Investment Purposes at End of Year

December 31, 2000

EIN# 38-1123360  
Plan# 002

(a)	(b)	(c) DESCRIPTION OF INVESTMENT INCLUDING MATURITY DATE, RATE OF INTEREST, COLLATERAL, PAR, OR MATURITY	(d) COST
Contract No. 401271		Wrapper Contract CITIBANK CC TRST 98-1 A CCIMT	
		Total Contract Value Interest rate: 4.89% Maturity date: 01/15/2001	5,134,1
Contract No. 401079		Wrapper Contract Autonation 00-A (A3) ANRC  MBIA	
		Total Contract Value Interest rate: 5.91% Maturity date: 01/15/2003	5,112,5
Contract No. 401080		Wrapper Contract FH 1615 G 5.5% 12/07 CMO PAC-1	
		Total Contract Value Interest rate: 6.01% Maturity date: 01/15/2003	4,574,5

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Contract No. 434193	Wrapper Contract FEDHMLN: 6.875% 1/15/05	
	Total Contract Value	5,119,8
	Interest rate: 7.13%	
	Maturity date: 01/17/2005	
Deutsche Bank AG (2 contracts) Contract No. FID-PUP-2	Wrapper Contract Fannie Mae 5.125% 2/13/04	
	Total Contract Value	5,940,5
	Interest rate: 6.18%	
	Maturity date: 02/13/2004	
Contract No. FID-PUP-1	Wrapper Contract FN93 225-TH 6% 6/23 PAC-I	
	Total Contract Value	7,133,2
	Interest rate: 5.55%	
	Maturity date: 06/25/2007	

20

25

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Assets Held for Investment Purposes at End of Year

December 31, 2000

EIN# 38-1123360  
Plan# 002

(a)	(b) IDENTITY OF ISSUE, BORROWER, LESSOR, OR SIMILAR PARTY	(c) DESCRIPTION OF INVESTMENT INCLUDING MATURITY DATE, RATE OF INTEREST, COLLATERAL, PAR, OR MATURITY	(d) COST
	Monumental Life Ins. Co ABS Insurance Co. (8 contracts) Contract No. BDA00379TR-02	Wrapper Contract Premier Auto Trust 1998-1 A4	
		Total Contract Value	4,119,6
		Interest rate: 5.70%	
		Maturity date: 04/08/2002	
	Contract No. BDA00379TR-04	Wrapper Contract Chase Manhattan Auto Trust 1998-B	
		Total Contract Value	4,437,4
		Interest rate: 5.25%	
		Maturity date: 09/16/2002	

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Contract No. BDA00379TR-05	Wrapper Contract Gen. Elec. Mtn. 5.35% 11/18/02	
	Total Contract Value	5,114,3
	Interest rate: 4.93%	
	Maturity date: 11/18/2002	
Contract No. BDA00379TR-07	Wrapper Contract DISCOVER 1999-1 (A) DCMT	
	Total Contract Value	7,131,6
	Interest rate: 5.33%	
	Maturity date: 02/15/2002	
Contract No. BDA00379TR-09	Wrapper Contract FN 94-30H 6.25% 11/22 CMO PACI	
	Total Contract Value	5,074,11
	Interest rate: 5.94%	
	Maturity date: 04/25/2007	
Contract No. BDA00379TR-14	Wrapper Contract DCAT00-D A3 6.66% 1 05	
	Total Contract Value	4,003,5
	Interest rate: 6.79%	
	Maturity date: 09/08/2003	

21

26

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Assets Held for Investment Purposes at End of Year

December 31, 2000

EIN# 38-1123360  
Plan# 002

(a)	(b) IDENTITY OF ISSUE, BORROWER, LESSOR, OR SIMILAR PARTY	(c) DESCRIPTION OF INVESTMENT INCLUDING MATURITY DATE, RATE OF INTEREST, COLLATERAL, PAR, OR MATURITY	(d) COST
	Contract No. BDA00379TR-13	Wrapper Contract FNR 98-36 PM 6.25%	
		Total Contract Value	4,878,4
		Interest rate: 7.19%	
		Maturity date: 10/18/2006	
	Contract No. BDA00379TR-11	Wrapper Contract	

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

	FEDHMLN 7% 2/15/2003	
	Total Contract Value	10,282,9
	Interest rate: 6.95%	
	Maturity date: 02/18/2003	
Morgan Guaranty (3 contracts)	Wrapper Contract	
Contract No. Upjohn2A	MBNA 97-F (A) MBNAM	
	Total Contract Value	6,016,3
	Interest rate: 6.69%	
	Maturity date: 06/17/2002	
Contract No. Upjohn04	Wrapper Contract	
	Newcourt 1998-1 (A3) NETS	
	Total Contract Value	2,356,7
	Interest rate: 5.29%	
	Maturity date: 12/20/2001	
Contract No. Upjohn05A	Wrapper Contract	
	CSFB 00-C1 A1 7.235%	
	Total Contract Value	5,006,8
	Interest rate: 7.05%	
	Maturity date: 07/15/2008	
Rabobank Nederland (3 contracts)	Wrapper Contract	
Contract No. UPJ109801	FH R1630 PG 5.75 4/20 PAC-I	
	Total Contract Value	4,748,6
	Interest rate: 5.15%	
	Maturity date: 11/15/2002	
Contract No. UPJ110001	Wrapper Contract	
	CARAT (GM) 2000-2 (A4)	
	CARAT	
	Total Contract Value	4,012,1
	Interest rate: 6.58%	
	Maturity date: 12/16/2002	

22

27

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Assets Held for Investment Purposes at End of Year

December 31, 2000

EIN# 38-1123360  
Plan# 002

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

(a)	(b) IDENTITY OF ISSUE, BORROWER, LESSOR, OR SIMILAR PARTY	(c) DESCRIPTION OF INVESTMENT INCLUDING MATURITY DATE, RATE OF INTEREST, COLLATERAL, PAR, OR MATURITY	(d) COST
	Contract No. UPJ050001	Wrapper Contract USTN 5.75% 4/30/03	
		Total Contract Value Interest rate: 6.89% Maturity date: 04/30/2003	6,905,0
*	State Street Bank & Trust Co. (4 contracts)	Wrapper Contract FNR 1993-41 PG	
	Contract No. 98114	Total Contract Value Interest rate: 5.88% Maturity date: 06/25/2002	2,904,5
	Contract No. 98006	Wrapper Contract FHR 1564 G	
		Total Contract Value Interest rate: 5.82% Maturity date: 02/18/2003	3,352,9
	Contract No. 98054	Wrapper Contract FHR 1618 G	
		Total Contract Value Interest rate: 5.87% Maturity date: 06/15/2003	3,955,5
	Contract No. 98115	Wrapper Contract FHR 1606 G	
		Total Contract Value Interest rate: 5.84% Maturity date: 10/15/2002	5,019,9
	UBS AG (5 contracts)		
	Contract No. 2315	Wrapper Contract AMCAR 1997-D A3	
		Total Contract Value Interest rate: 6.73% Maturity date: 10/07/2002	3,404,2

23

-----  
\* Represents a party-in-interest to the Plan.

28

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Assets Held for Investment Purposes at End of Year



Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

December 31, 2000

EIN# 38-1123360  
Plan# 002

(a)	(b) IDENTITY OF ISSUE, BORROWER, LESSOR, OR SIMILAR PARTY	(c) DESCRIPTION OF INVESTMENT INCLUDING MATURITY DATE, RATE OF INTEREST, COLLATERAL, PAR, OR MATURITY	(d) COST
	Contract No. 2316	Wrapper Contract Dayton Hudson 97-1 (A) DHMT  Total Contract Value Interest rate: 6.55% Maturity date: 10/25/2002	5,484,8
	Contract No. 2472	Wrapper Contract FNR 1994-85 E  Total Contract Value Interest rate: 5.46% Maturity date: 12/26/2001	1,782,2
	Contract No. 2605	Wrapper Contract HFCCM 99-PHI (A1) 6.5%  Total Contract Value Interest rate: 5.99% Maturity date: 02/15/2008	4,600,4
	Contract No. 2718	Wrapper Contract FHLMC GBLB 6.250% 10/15/02  Total Contract Value Interest rate: 6.47% Maturity date: 10/15/2002	5,049,96
	West Deutsche Landesbank (4 contracts)	Wrapper Contract CMAC 98-C2 A1 5.8% 3/06	
	Contract No. WLB6113	Total Contract Value Interest rate: 5.86% Maturity date: 07/15/2005	4,283,0
	Contract No. WLB6146	Wrapper Contract PP&L 1999-1 (A4) PPL  Total Contract Value Interest rate: 6.76% Maturity date: 12/26/2003	5,011,5
	Contract No. WLB6205	Wrapper Contract PNC Student Ln 97-2 (A5) PNC SL  Total Contract Value	4,023,2

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

Interest rate: 7.21%  
Maturity date: 07/25/2002

24

29

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Assets Held for Investment Purposes at End of Year

December 31, 2000

EIN# 38-1123360  
Plan# 002

(a)	(b) IDENTITY OF ISSUE, BORROWER, LESSOR, OR SIMILAR PARTY	(c) DESCRIPTION OF INVESTMENT INCLUDING MATURITY DATE, RATE OF INTEREST, COLLATERAL, PAR, OR MATURITY	(d) COST
	Contract No. WLB6202	Wrapper Contract FHR 1243 P 7.2% 4/07 PAC-I	
		Total Contract Value	5,001,9
		Interest rate: 7.46%	
		Maturity date: 06/15/2006	
	Total Synthetic Investment Contracts	- Contract Value	\$ 184,019,0
	Total Investment Contracts		\$ 214,166,2
	Participant loans:		
	Participant loans	Interest rate: 7% - 10.5%	\$
	Total Investments		\$1,141,144,0

25

30

THE PHARMACIA & UPJOHN EMPLOYEE SAVINGS PLAN

Schedule of Reportable Transactions

For the Year Ended December 31, 2000

(a) IDENTIFY OF PARTY INVOLVED	(b) DESCRIPTION OF ASSET	NUMBER OF TRANSACTIONS	(c) PURCHASE PRICE	(d) SELLING PRICE	(e) LEASE R
-----	-----	-----	-----	-----	-----

Edgar Filing: PHARMACIA CORP /DE/ - Form 11-K

*	Pharmacia Corporation	Pharmacia Corporation Common Stock	20 110	22,507,086 -	- 48,476,491
*	State Street Bank & Trust Company	Short-Term Investment Fund	209 315	108,124,262 -	- 110,313,575

(f) EXPENSE INCURRED WITH TRANSACTION -----	(g) COST OF ASSET -----	(h) CURRENT VALUE OF ASSET ON TRANSACTION DATE -----	(i) NET GAIN OR (LOSS) -----
-	22,507,086	22,507,086	-
-	13,472,384	48,476,491	35,004,107
-	108,124,262	108,124,262	-
-	110,313,575	110,313,575	-

-----  
\* Represents a party-in-interest to the Plan.

CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-34344) of Pharmacia Corporation of our report dated June 13, 2001 relating to the financial statements of the Pharmacia & Upjohn Employee Savings Plan, which appears in this Form 11-K.

/s/ PricewaterhouseCoopers LLP

-----  
PricewaterhouseCoopers LLP

Florham Park, New Jersey  
June 29, 2001